TUCSON, Ariz. (April 9, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Patrick Roche, Ph.D., has joined the company as Sr. Vice President for IVD Assay Development.Continue reading
Category Archives: AZBio News
AZBio CEO Makes the Case for Medical Innovation Investments in the Arizona Capitol Times
Saving money, improving lives – investing in medical innovation is a smart budget decisionContinue reading
PhRMA Report Looks at Alternate Growth Scenarios
New Report Reveals Growth Trajectories and Top Policy Factors Affecting Biopharmaceutical Innovation & Growth. New analysis incorporates real world insights from industry leadersContinue reading
Pfizer’s Ian Read succeeds Celgene’s Bob Hugin as PhRMA Board Chair
Pfizer’s Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New PostsContinue reading
BioPharm Insight: Regenesis now sees exit as sale to strategic player in 12 to 24 months – CEO
Regenesis Biomedical, a Scottsdale, Arizona-based medical device company, now sees a sale to a strategic in 2015 or 2016 as its likely exit, said CEO Scott Brooks.Continue reading
Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction
Capstone Therapeutics (OTCQB:CAPS) (“the Company”) and its joint venture affiliate, LipimetiX Development, LLC (“JV”), announced today the initiation of dosing for its AEM-28 (Apo E mimetic peptide) Phase 1 human clinical trial in LDL/non-HDL cholesterol reduction.Continue reading
Arizona’s Bioscience Roadmap: 2014-2025 Unveiled
PHOENIX—The strategic plan that has guided Arizona’s fast-growing bioscience sector for nearly 12 years is gearing up for a new decade.Continue reading
HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests
TUCSON, AZ–(Marketwired – Apr 7, 2014) – HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene expression assays on HTG’s fully automated, extraction-free Edge Platform.Continue reading
IMS Health Goes Public – IPO Raises $1.3 Billion
The IMS Health Holdings (NYSE:IMS) IPO represents the second-biggest IPO so far this year in the U.S.
IMS Heath’s IMS One portfolio of products includes 360 Vantage|IMS Health (Chandler, AZ). 360 Vantage was acquired by IMS Heath in May of 2013.